Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss

Reuters

2025/12/04

Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss

Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2588884143"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588884143\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588884143?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588884143","market":"fut","top_or_hot":-1,"title":"Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL367TTr:1","article_id":"2588884143","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588884143","pubTimestamp":1764853216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor  antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","BK4121":"生命科学工具和服务","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","ABSI":"Absci Corporation.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4539":"次新股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Absci在人工智能设计的脱发抗体1/2期试验中为第一批志愿者注射药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ABSI":0.9},"content_text":"Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n    \n\n        Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}